Picture of Protagonist Therapeutics logo

PTGX — Protagonist Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

Protagonist Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

* Protagonist Therapeutics Inc  PTGX.OQ  reported quarterly
adjusted earnings of $3.26​​ per share for the quarter ended in
March, higher than the same quarter last year, when the company
reported EPS of -67 cents.  The mean expectation of
five analysts for the quarter was for earnings of $1.19 per
share. Wall Street expected results to range from -62 cents
to $3.95 per share.
    * Revenue was $254.95 million​; analysts expected $120.00
million. 
    * Protagonist Therapeutics Inc's reported EPS for the
quarter was
$3.26​.
    * The company reported quarterly net income of $207.34
million.
    * Protagonist Therapeutics Inc shares had fallen by 10.9%
this
quarter and gained 12.5% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 76.9%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Protagonist
Therapeutics Inc is $45.00 
This summary was machine generated from LSEG data May 8 at 07:39
a.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      1.19           3.26           Beat
 Dec. 31 2023      -0.03          0.44           Beat
 Sep. 30 2023      -0.69          -0.58          Beat
 Jun. 30 2023      -0.65          -0.68          Missed

Recent news on Protagonist Therapeutics

See all news